“…The S. venezuelae strain used at the John Innes Centre (JIC) was obtained from Diversa Corporation (San Diego, USA) in 2003 and described as strain ATCC 10712; the company had in turn obtained it from the Vining laboratory (Doull et al., 1985 ). In addition to chloramphenicol (Fernández-Martínez et al., 2014 ), this strain also produces the polyketide antibiotic jadomycin B (Doull et al., 1993 , 1994 ; Jakeman et al., 2006 ), which also has antitumour activity (Hall et al., 2015 ), and its congeners (Robertson et al., 2015 ), as well as the biaryl polyketide venemycin (Thanapipatsiri et al., 2016 ), the non-ribosomal peptide watasemycin (Inahashi et al., 2017 ), the γ-aminobutyrate-derived gaburedins (Sidda et al., 2013 ), and the indole arcyriaflavin (Mervyn Bibb, unpublished data); it also has the potential to produce a novel lanthipeptide, venezuelin (Goto et al., 2010 ). At the same time, Diversa Corporation also kindly provided a genome sequence of the strain that had been obtained by whole-genome shotgun Sanger sequencing (GenBank Accession No.…”